Vicore Pharma (VCRE) Stock Price, News & Analysis

Company Overview

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor. The company is evaluating buloxibutid in clinical studies for idiopathic pulmonary fibrosis and related interstitial lung diseases, with the aim of improving lung function and limiting disease progression.

Founded in Sweden, Vicore Pharma conducts research and clinical development activities through international collaborations and studies. Its pipeline has also included programs designed to support patients with pulmonary diseases and associated health challenges. The company is headquartered in Gothenburg, Sweden, and its shares are publicly traded under the symbol VCRE.

Key Stats

• Today's Range: $8.89 to $9.25
• 50-Day Range: N/A
• 52-Week Range: $7.88 to $17.80
• Volume: 27,754 shs
• Average Volume: 27,961 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VCRE
• CIK: 2124403
• Web: vicorepharma.com
• Phone: +460317880560
• Fax: N/A
• Employees: 37
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vicore Pharma: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +179.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.99 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A